Dosage Lookup

Rapamycin

2.6

Moderate

consensus

Based on expert consensus data from publicly available videos, not medical advice. Always consult your healthcare provider before starting, stopping, or changing any supplement.

Consensus Protocol

Dosage

  • No consensus among the 5 experts
  • Attia uses low-dose intermittent protocols in clinical practice but emphasizes there are no clear biomarkers to guide optimal dosing
  • Common off-label longevity dosing discussed in the literature is 3-6mg once weekly, but this is not standardized
  • Johnson tried multiple dosing protocols before discontinuing entirely

Form

  • Sirolimus (rapamycin) is a prescription pharmaceutical, not an over-the-counter supplement
  • It requires a physician's prescription and monitoring
  • FDA-approved for organ transplant rejection prevention

Timing

  • Intermittent dosing (typically once weekly) is the approach discussed for longevity use, as opposed to the daily high-dose regimen used in transplant medicine
  • The goal is to preferentially inhibit mTORC1 while allowing mTORC2 recovery between doses (Attia)

Notes

  • Rapamycin is a prescription drug, not a supplement — it requires medical supervision and regular blood monitoring
  • Attia emphasizes thorough discussion of risks and uncertainties with patients before prescribing
  • Johnson's experience demonstrates that even with extensive medical oversight, side effects can outweigh perceived benefits
  • This is NOT a self-medication candidate

Expert Positions

Andrew Huberman
Andrew Huberman
Explicitly Avoids It
Peter Attia
Peter Attia
Cautiously Prescribes to Patients
Rhonda Patrick
Rhonda Patrick
Discusses mTOR, Not Rapamycin
Bryan Johnson
Bryan Johnson
Tried and Discontinued
Mark Hyman
Mark Hyman
Mentions Favorably, No Protocol

What Each Expert Says

Andrew Huberman
Andrew Huberman
Explicitly Avoids It

Huberman discusses rapamycin across 2 videos with a clear personal stance: he avoids it. In his dedicated longevity supplements AMA, he explicitly states he avoids metformin, berberine, and rapamycin, citing lack of sufficient human data for longevity and the presence of significant side effects. In his interview with Dr. David Fajgenbaum, rapamycin appears in the context of drug repurposing — Fajgenbaum discovered that sirolimus (rapamycin) could treat his terminal Castleman disease, which was originally approved for organ transplant rejection. This episode frames rapamycin as a powerful drug with multiple pathways but does not endorse it for longevity.

Unlock Expert Deep Dives

See exactly what each expert recommends — specific dosages, forms, timing protocols, and video citations with timestamps.

Cancel anytime

More on Rapamycin